- Home
- TNGX vs TSSI Comparison
TNGX vs TSSI Comparison
Compare TNGX & TSSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- TSSI
- Stock Information
- Founded
- TNGX 2014
- TSSI 2004
- Country
- TNGX United States
- TSSI United States
- Employees
- TNGX N/A
- TSSI N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- TSSI Professional Services
- Sector
- TNGX Health Care
- TSSI Consumer Discretionary
- Exchange
- TNGX Nasdaq
- TSSI Nasdaq
- Market Cap
- TNGX 723.2M
- TSSI 677.8M
- IPO Year
- TNGX N/A
- TSSI N/A
- Fundamental
- Price
- TNGX $6.90
- TSSI $15.40
- Analyst Decision
- TNGX Strong Buy
- TSSI
- Analyst Count
- TNGX 6
- TSSI 0
- Target Price
- TNGX $10.00
- TSSI N/A
- AVG Volume (30 Days)
- TNGX 1.9M
- TSSI 3.5M
- Earning Date
- TNGX 08-05-2025
- TSSI 08-06-2025
- Dividend Yield
- TNGX N/A
- TSSI N/A
- EPS Growth
- TNGX N/A
- TSSI 311.74
- EPS
- TNGX N/A
- TSSI 0.34
- Revenue
- TNGX $24,296,000.00
- TSSI $263,021,000.00
- Revenue This Year
- TNGX N/A
- TSSI N/A
- Revenue Next Year
- TNGX N/A
- TSSI N/A
- P/E Ratio
- TNGX N/A
- TSSI $43.93
- Revenue Growth
- TNGX N/A
- TSSI 328.79
- 52 Week Low
- TNGX $1.03
- TSSI $4.13
- 52 Week High
- TNGX $12.02
- TSSI $31.94
- Technical
- Relative Strength Index (RSI)
- TNGX 56.63
- TSSI 33.85
- Support Level
- TNGX $6.60
- TSSI $13.88
- Resistance Level
- TNGX $7.42
- TSSI $15.63
- Average True Range (ATR)
- TNGX 0.47
- TSSI 1.96
- MACD
- TNGX -0.04
- TSSI -0.80
- Stochastic Oscillator
- TNGX 57.20
- TSSI 8.52
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About TSSI TSS Inc. Common Stock
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.